Skip to main content

Table 1 Patient characteristics at baseline

From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

 

All

(n = 409)

irAEs ( +)

(n = 138)

irAEs (-)

(n = 271)

P value

Age, years

69 (60–74)

70 (60–74)

69 (60–74)

0.32

Gender (male)

288 (70.4)

94 (68.7)

194 (71.6)

0.49

BMI, kg/m2

20.9 (18.1–23.4)

21.7 (18.5–24.0)

20.5 (17.9–23.2)

0.04

Pulse rate, bpm

82 (73–93)

81 (71–91)

84 (74–94)

0.12

Systolic blood pressure, mmHg

120 (107–134)

123 (111–134)

118 (106–133)

0.14

Diastolic blood pressure, mmHg

72 (64–81)

72 (64–81)

72 (64–82)

0.70

Cancer type

 Non-small cell lung cancer

170 (41.6)

59 (42.8)

111 (41.0)

0.75

 Malignant melanoma

82 (20.0)

42 (30.4)

40 (14.8)

 < 0.01

 Renal cancer

43 (10.5)

20 (14.5)

23 (8.5)

0.09

 Stomach cancer

35 (8.6)

4 (2.9)

31 (11.4)

0.003

 Pharyngeal cancer

21 (5.1)

3 (2.2)

18 (6.6)

0.059

 Paranasal cancer

7 (1.7)

2 (1.4)

5 (1.8)

1

 Tongue cancer

7 (1.7)

1 (0.7)

6 (2.2)

0.43

 Bladder cancer

6 (1.5)

1 (0.7)

5 (1.8)

0.67

 Mesothelioma

5 (1.2)

0 (0)

5 (1.8)

0.17

 Other cancer

33 (8.1)

6 (4.3)

27 (10.0)

0.056

Comorbidity

 Hypertension

162 (39.6)

60 (43.5)

102 (37.6)

0.29

 Diabetes mellitus

74 (18.1)

27 (19.6)

47 (17.3)

0.59

 Dyslipidemia

72 (17.6)

31 (22.5)

41 (15.1)

0.075

Cardiovascular history

 Coronary artery disease

34 (8.3)

15 (10.9)

19 (7.0)

0.19

 Arrythmia

24 (5.9)

11 (8.0)

13 (4.8)

0.27

 Heart failure

5 (1.2)

2 (1.4)

3 (1.1)

1

 Venous thrombosis

8 (2.0)

0 (0)

8 (3.0)

0.06

 Pericardial disease

3 (0.7)

0 (0)

3 (1.1)

0.55

Medication

 ACE-I/ARB

81 (19.8)

35 (25.4)

47 (17.3)

0.067

 Beta-blockers

34 (8.3)

15 (10.9)

19 (7.0)

0.26

 Ca-channel blockers

118 (28.9)

43 (31.2)

75 (27.7)

0.49

 Statins

57 (13.9)

23 (16.7)

34 (12.5)

0.29

 Diuretics

28 (6.8)

6 (4.3)

27 (10.0)

0.21

Laboratory measurements

 TP, mg/dL

6.8 (6.3–7.1)

6.8 (6.5–7.0)

6.7 (6.3–7.2)

0.37

 Alb, mg/dL

3.7 (3.3–4.0)

3.8 (3.4–4.1)

3.7 (3.2–4.0)

0.01

 Cre, mg/dL

0.79 (0.65–1.00)

0.78 (0.64–1.00)

0.79 (0.65–1.00)

0.91

 CRP, md/dL

0.42 (0.10—1.80)

0.23 (0.07—1.12)

0.56 (0.13 – 2.28)

0.004

 WBC, /103

6.0 (4.9—7.7)

5.9 (4.9 – 7.3)

6.0 (4.9—7.8)

0.44

 Hb, mg/dL

11.8 (10.4–13.0)

12.0 (10.9–13.2)

11.7 (10.3–12.9)

0.033

Chest radiography

 CTR, %

46.5 (42.6–50.1)

46.8 (42.8–50.2)

46.3 (42.5–50.1)

0.56

  1. irAEs immune-Related Adverse Events, BMI body mass index, ACE-I angiotensin-converting-enzyme inhibitor, ARB Angiotensin II Receptor Blocker, TP total protein, Alb albumin, Cre creatinine, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, CTR cardiothoracic ratio